EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro CB1 receptor activity of halogenated indazole synthetic cannabinoid receptor agonists

Henrik Green iD, Craig McKenzie iD, Elias Hamra, Tobias Rautio iD, Xiongyu Wu iD, Emma Juneskog, Rebecka Sandblom, Manuela Carla Monti iD, Mattias Persson iD, Caitlyn Norman iD

Archives of Toxicology · 2025

DOI: 10.1007/s00204-025-04082-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Toxicology, 2025. Verfasst von Henrik Green und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Clinical Science, Division of Clinical Chemistry and Pharmacology, Linköping University, Linköping, Sweden. Hauptthemen laut MEDLINE: Indazoles, Receptor, Cannabinoid, CB1, Cannabinoid Receptor Agonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eurostars, VINNOVA, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synthetic cannabinoid receptor agonists (SCRAs) are a group of new psychoactive substances (NPS) that bind to and activate the cannabinoid 1 and 2 (CB 1 and CB 2 ) receptors. Following the introduction of SCRA analog controls in China in July 2021, new SCRAs with a bromine at the 5 position on the indazole core emerged on the recreational drug market. In this study, the in vitro CB 1 receptor activity of 19 different SCRAs with a halogenated indazole core was systematically examined using a AequoScreen ® CB 1 assay alongside four available non-halogenated analogs, ADB-BUTINACA, MDMB-BUTINACA, MDMB-4en-PINACA, and MDMB-INACA, and the newly emerged MDMB-5′Me-INACA (MDMB-5-methyl-INACA). Of SCRAs with a substitution at the 5 position on the indazole core, analogs with a fluorine had the lowest EC 50 values. For SCRAs with a methyl ester head moiety (MMB or MDMB), chlorinated analogs had the next lowest EC 50 values followed by brominated analogs; however, the opposite relationship was observed for SCRAs with an amide head moiety (AB or ADB). All halogenated compounds had similar potency to their non-halogenated analog, except the brominated tert -leucine methyl ester SCRAs, which had significantly reduced potency. Of the different head moieties, tert -leucine methyl ester SCRAs were the most potent, followed by tert -leucinamide, valinamide, and valine methyl ester. The potencies of the SCRAs with pentyl (ADB-5′Br-PINACA/ADMB-5′Br-PINACA/ADB-P-5′Br-INACA), pent-4-enyl (ADB-4en-5′Br-PINACA/ADMB-4en-5′Br-PINACA/ADB-4en-P-5′Br-INACA and MDMB-4en-5′Br-PINACA/MDMB-4en-P-5′Br-INACA), and butyl tails (ADB-5′Br-BUTINACA/ADMB-5′Br-BUTINACA/ADB-B-5′Br-INACA) were not significantly different, whereas fluorobenzyl (ADB-5′Br-FUBINACA), tail-less (ADB-5′Br-INACA), and decyl tail (ADB-5′Br-DECINACA/ADMB-5′Br-DECINACA/ADB-D-5′Br-INACA) analogs were significantly less potent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndazolesReceptor, Cannabinoid, CB1Cannabinoid Receptor AgonistsHumansAnimalsHalogenationStructure-Activity RelationshipCHO Cells

Stichwörter der Autor:innen

CB1 cannabinoid receptorHalogenated synthetic cannabinoid receptor agonistsNew psychoactive substancesPotencyStructure–activity relationships

Substanzen

IndazolesReceptor, Cannabinoid, CB1Cannabinoid Receptor Agonists

Autor:innen und Institutionen

  • Department of Biomedical and Clinical Science, Division of Clinical Chemistry and Pharmacology, Linköping University, Linköping, Sweden.
  • Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping, Sweden.
  • Chiron AS, Trondheim, Norway.
  • Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden.
  • Department of Biomedical and Clinical Science, Division of Clinical Chemistry and Pharmacology, Linköping University, Linköping, Sweden. caitlyn.norman@liu.se.

ORCID-Profile: Henrik Green, Craig McKenzie, Tobias Rautio, Xiongyu Wu, Manuela Carla Monti, Mattias Persson, Caitlyn Norman

Förderung

  • Eurostars
  • VINNOVA
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Horizon 2020
  • Strategiområdet forensiska vetenskaper
  • Linköping University

Zitieren

APA

Green, H., McKenzie, C., Hamra, E., Rautio, T., Wu, X., Juneskog, E., Sandblom, R., Monti, M. C., Persson, M., & Norman, C. (2025). In vitro CB1 receptor activity of halogenated indazole synthetic cannabinoid receptor agonists. Archives of Toxicology. https://doi.org/10.1007/s00204-025-04082-4

Vancouver

Green H, McKenzie C, Hamra E, Rautio T, Wu X, Juneskog E, et al. In vitro CB1 receptor activity of halogenated indazole synthetic cannabinoid receptor agonists. Archives of Toxicology. 2025. doi:10.1007/s00204-025-04082-4

BibTeX
@article{Green2025,
  author = {Green, Henrik and McKenzie, Craig and Hamra, Elias and Rautio, Tobias and Wu, Xiongyu and Juneskog, Emma and Sandblom, Rebecka and Monti, Manuela Carla and Persson, Mattias and Norman, Caitlyn},
  title = {In vitro CB1 receptor activity of halogenated indazole synthetic cannabinoid receptor agonists},
  journal = {Archives of Toxicology},
  year = {2025},
  doi = {10.1007/s00204-025-04082-4}
}
Kostenlos starten →